Stephen D Hess

US Patent:

6413764, Jul 2, 2002

Filed:

Sep 15, 1998

Appl. No.:

09/153757

Inventors:

Lorrie Daggett - San Diego CA
Steven B. Ellis - San Diego CA
Chen Liaw - San Diego CA
Aaron Pontsler - West Jordan UT
Edwin C. Johnson - San Diego CA
Stephen D. Hess - San Diego CA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12N 121

US Classification:

4352523, 4352528, 4352542, 43525421, 43525422, 4352543, 4353201, 435325, 536 231

Abstract:

In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e. g. , agonists, antagonists, and modulators of glutamate receptor function.

US Patent:

6485919, Nov 26, 2002

Filed:

Dec 13, 1999

Appl. No.:

09/459715

Inventors:

Lorrie Daggett - San Diego CA
Steven B. Ellis - San Diego CA
Chen Liaw - San Diego CA
Aaron Pontsler - West Jordan UT
Edwin C. Johnson - San Diego CA
Stephen D. Hess - San Diego CA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

G01N 33567

US Classification:

435 721, 435 72, 435 71, 435325, 435364, 435365, 435366, 4352521, 4352542, 530350

Abstract:

In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e. g. , agonists, antagonists, and modulators of glutamate receptor function.

US Patent:

6956049, Oct 18, 2005

Filed:

Aug 31, 1999

Appl. No.:

09/387135

Inventors:

Nicholas D. P. Cosford - San Diego CA, US
Ian A. McDonald - San Diego CA, US
Stephen D. Hess - San Diego CA, US
Mark A. Varney - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K031/425
A51K031/425
C07D277/00

US Classification:

514365, 514369, 514370, 514371, 514372, 548146

Abstract:

In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.

US Patent:

8133695, Mar 13, 2012

Filed:

Feb 27, 2009

Appl. No.:

12/394605

Inventors:

David Piper - Madison WI, US
Kurt Vogel - Madison WI, US
Mohammed Saleh Shekhani - Madison WI, US
Stephen Hess - Verona WI, US
Steve Duff - Middleton WI, US
Thomas Livelli - Madison WI, US
Zhong Zhong - Shanghai, CN

Assignee:

Life Technologies Corporation - Carlsbad CA

International Classification:

G01N 33/53
G01N 33/532
G01N 33/533

US Classification:

435 793, 435 71, 436544, 436546, 436 56

Abstract:

Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K channel, and the propensity of a test compound to influence that binding interaction.

US Patent:

20010056084, Dec 27, 2001

Filed:

Mar 29, 2001

Appl. No.:

09/821416

Inventors:

Hans Allgeier - Lorrach, DE
Nicholas Cosford - San Diego CA, US
Peter Flor - Basel, CH
Fabrizio Gasparini - Lausen, CH
Conrad Gentsch - Binningen, CH
Stephen Hess - San Diego CA, US
Edwin Johnson - San Diego CA, US
Rainer Kuhn - Lorrach, DE
Mark Tricklebank - Teddington, GB
Laszlo Urban - London, GB
Mark Varney - San Diego CA, US
Gonul Velicelebi - San Diego CA, US
Katharine Walker - London, GB

International Classification:

A61K031/655
A61K031/5377
A61K031/495
A61K031/4545
A61K031/444

US Classification:

514/151000, 514/233200, 514/253010, 514/332000, 514/318000

Abstract:

The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.

US Patent:

20120231541, Sep 13, 2012

Filed:

Mar 9, 2012

Appl. No.:

13/417008

Inventors:

David Piper - Madison WI, US
Stephen Hess - Verona WI, US
Mohammed Saleh Shekhani - Madison WI, US
Thomas Livelli - Madison WI, US
Zhong Zhong - Shanghai, CN
Steve Duff - Middleton WI, US
Kurt Vogel - Madison WI, US

Assignee:

LIFE TECHNOLOGIES CORPORATION - Carlsbad CA

International Classification:

C12N 5/071
C12N 5/10
C12N 5/073

US Classification:

435361, 435358, 435369

Abstract:

Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K channel, and the propensity of a test compound to influence that binding interaction.

US Patent:

58076891, Sep 15, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/486270

Inventors:

Lorrie Daggett - San Diego CA
Steven B. Ellis - San Diego CA
Chen Liaw - San Diego CA
Aaron Pontsler - West Jordan UT
Edwin C. Johnson - San Diego CA
Stephen D. Hess - San Diego CA

Assignee:

Sibia Neurosciences, Inc. - La Jolla CA

International Classification:

G01N 3353
C12P 2102
C12N 1563
C12N 1509

US Classification:

435 78

Abstract:

In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e. g. , agonists, antagonists, and modulators of glutamate receptor function.

US Patent:

D2532999, Oct 30, 1979

Filed:

Apr 28, 1978

Appl. No.:

5/901272

Inventors:

Stephen W. Hess - Westminster CA

International Classification:

D2302

US Classification:

D23 57